13 completed, 2 unknown, 2 withdrawn, 1 active not recruiting. 5 Not applicable, 5 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow BRCA1 Mutation Carrier: new trials by email Literature Review of BRCA1 Mutation Carrier trials Research Report on BRCA1 Mutation Carrier
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Telapristone Acetate, Placebo, Laboratory Biomarker Analysis - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 2 | Completed | Northwestern University | 67 | 2015-10-01 | 2023-02-22 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer counseling intervention, behavioral dietary intervention, exercise intervention - Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia | Not applicable | Completed | University of Washington | 17 | 2013-10-01 | 2016-01-20 |
| Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Veliparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2012-04-09 | 2019-07-23 |
| S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer cholecalciferol, placebo - brca1 Mutation Carrier, brca2 Mutation Carrier | Not applicable | Completed | SWOG Cancer Research Network | 208 | 2011-11-01 | 2017-11-24 |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors veliparib, capecitabine, oxaliplatin - Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach | Phase 1 | Terminated | National Cancer Institute (NCI) | 16 | 2010-10-01 | 2014-04-02 |
| Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer soy isoflavones, placebo, questionnaire administration - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Not applicable | Completed | University of Southern California | 110 | 2010-07-01 | 2023-11-18 |
| ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors Diagnostic Laboratory Biomarker Analysis, Gemcitabine Hydrochloride, Pharmacological Study - Adult Solid Neoplasm, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2010-05-01 | 2015-07-02 |
| Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer Biomarker LPA and HE4 - brca1 Mutation Carrier, brca2 Mutation Carrier | Completed | Women and Infants Hospital of Rhode Island | 525 | 2009-06-01 | 2018-01-05 | |
| Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Laboratory Biomarker Analysis, Pharmacological Study, Veliparib - Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 98 | 2009-04-20 | 2018-06-29 |
| Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers Laboratory Biomarker Analysis - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Withdrawn | Gynecologic Oncology Group | 2008-05-01 | 2017-07-13 | ||
| Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation letrozole, Placebo - brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 3 | Completed | UNICANCER | 170 | 2008-05-01 | 2024-07-01 |
| Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers DNA analysis, mutation analysis, polymorphism analysis - brca1 Mutation Carrier, brca2 Mutation Carrier | Unknown | Gynecologic Oncology Group | 10000 | 2008-04-01 | 2011-03-23 | |
| Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting - brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 2 | Completed | Cancer Research UK | 78 | 2007-12-01 | 2016-05-24 |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 107 | 2007-09-01 | 2015-05-22 |
| Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer carboplatin, docetaxel - brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 2 | Completed | University College London Hospitals | 148 | 2005-09-01 | 2013-08-26 |
| Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries fenretinide - brca1 Mutation Carrier, brca2 Mutation Carrier | Not applicable | Completed | University of Arizona | 40 | 2004-10-01 | 2010-03-24 |
| Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease therapeutic estradiol, deslorelin, therapeutic testosterone - brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 2 | Unknown | City of Hope Medical Center | 11 | 2004-03-11 | 2024-08-28 |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy celecoxib, oophorectomy - brca1 Mutation Carrier, brca2 Mutation Carrier | Not applicable | Withdrawn | University of Alabama at Birmingham | 2002-06-01 | 2013-08-22 |
Breast Neoplasms (12) · Ovarian Neoplasms (7) · Carcinoma, Ovarian Epithelial (5) · Breast Carcinoma In Situ (4) · Carcinoma, Intraductal, Noninfiltrating (4) · Hereditary Breast and Ovarian Cancer Syndrome (4) · Fallopian Tube Neoplasms (3) · Pancreatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Colonic Neoplasms (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1)
Neoplasms (18) · Neoplasms by Site (18) · Breast Diseases (14) · Skin Diseases (14) · Skin and Connective Tissue Diseases (14) · Adnexal Diseases (11) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases (11) · Genital Diseases, Female (11) · Genital Neoplasms, Female (11) · Gonadal Disorders (11) · Ovarian Diseases (11)
veliparib (5) · Carboplatin (2) · Immunohistochemistry (2) · Amplified Fragment Length Polymorphism Analysis (1) · Biopsy (1) · Blotting, Western (1) · Capecitabine (1) · Celecoxib (1) · Cholecalciferol (1) · Chromatography, Liquid (1) · Counseling (1) · Docetaxel (1) · Estradiol (1) · Fenretinide (1) · Gemcitabine (1)
National Cancer Institute (NCI) (5) · Gynecologic Oncology Group (2) · Cancer Research UK (1) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · SWOG Cancer Research Network (1) · UNICANCER (1) · University College London Hospitals (1) · University of Alabama at Birmingham (1) · University of Arizona (1) · University of Southern California (1) · University of Washington (1) · Women and Infants Hospital of Rhode Island (1)
United States (16) · United Kingdom (2) · Australia (1) · France (1) · Israel (1) · Portugal (1) · Spain (1) · Sweden (1)
Andrew Tutt, MD, PhD, FRCR, MBBS, MRCP (1) · Anna Wu (1) · Edward E. Partridge, MD (1) · Jeffrey Weitzel, MD (1) · Katherine D. Crew, MD, MS (1) · Kerryn Reding (1) · Mark Greene (1) · Mark H. Greene, MD (1) · Michael Birrer, MD, PhD (1) · Molly A. Brewer, MD, DVM, MS (1) · Pascal Pujol, MD (1) · Phuong Mai, MD (1) · Richard G Moore, MD (1) · Robert Coleman (1) · Ronald Stoller (1)
PMID 26276750, PMID 30616442, PMID 32379297, PMID 35435472
P30CA047904 (3), U01CA099168 (3), N01CM00038 (1), P30CA014520 (1), P30CA015704 (1), P30CA016672 (1), P30CA033572 (1), P50CA083639 (1), R00NR012232 (1), U01CA062491 (1), U01CA062505 (1), U01CA132194 (1), U10CA027469 (1), U10CA037429 (1), U10CA101165 (1)